• GSK-923295 and the New Frontier of Centromere-Targeted Cance

  2026-05-24

  Explore how the CENP-E inhibitor GSK-923295 enables precision dissection of mitotic fidelity, bridging mechanistic centromere biology with translational oncology. This article synthesizes recent findings on CTCF's centromere function and provides strategic guidance for researchers aiming to leverage GSK-923295 in advanced cancer models, with actionable protocol parameters and a look at emerging translational opportunities.

• Redefining DNA Replication Control with ddATP: Mechanisms an

  2026-05-23

  This thought-leadership article explores the mechanistic and strategic use of ddATP (2',3'-dideoxyadenosine triphosphate) in translational research. Integrating recent findings on DNA double-strand break repair in oocytes, the article bridges bench science with practical guidance, showcasing APExBIO's ddATP as a pivotal tool for controlled DNA synthesis termination, pathway interrogation, and next-generation clinical innovation. It critically situates ddATP within the competitive landscape, links to actionable protocols, and offers a forward-looking perspective on the evolving role of chain-terminating nucleotides in molecular biology.

• iPSC-Based Drug Screening for Ultrarare Disease: A Clinical

  2026-05-22

  This study establishes a patient-specific induced pluripotent stem cell (iPSC) platform to prescreen drug efficacy and safety for individuals with ultrarare Leigh-like syndrome. Its innovation lies in enabling personalized, evidence-driven clinical trial selection, addressing a critical gap for patients with novel pathogenic mutations.

• CHIR-99021 (CT99021): Advancing Stem Cell Pluripotency & Dif

  2026-05-22

  CHIR-99021 (CT99021) is redefining the reproducibility of stem cell workflows by providing high selectivity and robust GSK-3 inhibition. Explore how this compound unlocks new precision in maintaining pluripotency, directing differentiation, and troubleshooting Wnt/β-catenin signaling modulation.

• Angiotensin III (human, mouse): Advanced Mechanistic Insight

  2026-05-21

  Explore the multifaceted roles of Angiotensin III in cardiovascular and viral pathogenesis research. This article offers an in-depth analysis of its mechanism, application protocols, and recent insights from peptide-receptor interaction studies.

• CXCL1-CXCR2 Axis Drives Microglial Activation in NTS and Can

  2026-05-21

  The reference study uncovers a central mechanism by which CXCL1-CXCR2 signaling in the nucleus tractus solitarii (NTS) activates microglia to drive pancreatic cancer-induced pain. These findings highlight new targets within the central nervous system for alleviating cancer pain and underscore the need to integrate advanced cytokine assays in neuroinflammatory research.

• GW4064: Non-Steroidal FXR Agonist Advancing Metabolic Assays

  2026-05-20

  GW4064 enables rigorous, targeted investigation of FXR-regulated pathways in metabolic, fibrotic, and ferroptosis-related research. Its precision as a non-steroidal FXR agonist unlocks new experimental strategies, despite handling and solubility challenges.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-05-20

  Xiao et al. (2024) reveal that 25-hydroxycholesterol (25HC) accumulates in tumor-associated macrophages, activating AMPKα via lysosomal signaling, which reprograms macrophages toward an immunosuppressive phenotype. This mechanistic insight highlights CH25H and 25HC as immunometabolic checkpoints and provides a rationale for targeting these pathways to enhance anti-tumor immunity.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Mechanism & Bes

  2026-05-19

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) is an advanced in vitro transcribed reporter mRNA designed for robust gene expression and bioluminescent assays. Its ARCA capping and nucleotide modifications enhance translation, stability, and reduce immunogenicity, enabling precise, reproducible results in cell viability and in vivo imaging studies.

• Diclofenac as a Non-Selective COX Inhibitor: Protocol Precis

  2026-05-19

  Explore the advanced application of Diclofenac as a non-selective COX inhibitor in precise pharmacokinetic and inflammation signaling pathway research. This article uniquely bridges compound handling, organoid integration, and protocol design for next-generation drug discovery workflows.

• Elobixibat Hydrate in Novel Bowel Prep: Insights from the E-

  2026-05-18

  The E-PLUS trial protocol by Hotta et al. presents a patient-centered comparative study of elobixibat hydrate plus sodium picosulfate/magnesium citrate versus standard polyethylene glycol/ascorbic acid for colonoscopy bowel preparation. This multicenter design aims to optimize cleansing efficacy and tolerability, potentially reshaping clinical approaches to bowel prep.

• CTCF is Essential for Centromere Function and Mitotic Fideli

  2026-05-18

  This study demonstrates that CTCF is a key factor in maintaining centromere integrity and accurate chromosome segregation during mitosis. Rapid depletion of CTCF reveals mechanistic differences from CENP-E, providing new insight into mitotic regulation and offering a foundation for targeted cell cycle research.

• Applied Use-Cases of 12-O-tetradecanoyl phorbol-13-acetate (

  2026-05-17

  Harness 12-O-tetradecanoyl phorbol-13-acetate (TPA) for precise, reproducible ERK/MAPK pathway activation across cancer, neurobiology, and signal transduction assays. This guide translates the latest mechanistic insights and troubleshooting strategies into actionable workflows, helping researchers maximize data quality and experimental value with APExBIO’s trusted TPA.

• Applied Workflows with Angiotensin I in Cardiovascular Resea

  2026-05-16

  Unlock the full translational potential of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) by leveraging robust, evidence-based protocols for renin-angiotensin system research and antihypertensive drug screening. This article details advanced experimental workflows, troubleshooting strategies, and the latest innovations in spectral interference removal, positioning APExBIO as a trusted partner for reproducibility in cardiovascular and neuroendocrine modeling.

• Anlotinib Hydrochloride: Multi-Target Inhibition of Angiogen

  2026-05-15

  This study demonstrates that anlotinib hydrochloride, a novel multi-target tyrosine kinase inhibitor, suppresses angiogenesis by concurrently inhibiting VEGFR2, PDGFRβ, and FGFR1 activation. The findings offer mechanistic and comparative evidence that anlotinib outperforms established angiogenesis inhibitors in both vitro and in vivo assays, highlighting its potential for translational cancer research.

14399 records 1/960 page Next 12345 下5页 Last page